Advertisement

Advertisement

gynecologic cancers

Alice P. Barr, MD, on Advanced Ovarian Cancer: Minimally Invasive vs Open Surgery After Chemotherapy

Alice P. Barr, MD, of the Carolinas Medical Center and Levine Cancer Institute, discusses results from a retrospective study, which showed that progression-free and overall survival appeared to be no different with open surgery and minimally invasive surgery for interval debulking after neoadjuvant chemotherapy in women with advanced epithelial ovarian cancer. Perioperative outcomes also seemed to be superior with minimally invasive surgery (ID #10209).

Gynecologic Cancers

Image-Guided Intensity-Modulated Radiotherapy in Patients With Cervical Cancer

Treatment with image-guided intensity-modulated radiotherapy (IG-IMRT) led to reduced late toxicities vs standard three-dimensional (3D) conformal radiotherapy in patients with cervical cancer, according to data presented by Supriya Chopra, MD, and colleagues during the Society of Gynecologic...

Gynecologic Cancers
Immunotherapy

Niraparib Plus Bevacizumab Shows Clinical Benefit in Patients With Advanced Ovarian Cancer

The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the Society of Gynecologic Oncology...

gynecologic cancers
genomics/genetics
immunotherapy

Charles N. Landen, MD, on Newly Diagnosed Ovarian Cancer: BRCA Mutations, PD-L1 Expression, and Combination Chemoimmunotherapy

Charles N. Landen, MD, of the University of Virginia, discusses results from the first clinical trial in ovarian cancer to demonstrate that neither a BRCA1/2 mutation nor a homologous recombination deficiency improves sensitivity to a therapeutic PD-L1 blockade in patients receiving atezolizumab vs placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed disease (ID #10240).

gynecologic cancers
immunotherapy

Hyun C. Chung, MD, on Pembrolizumab for Advanced Cervical Cancer: Update From KEYNOTE-158

Hyun C. Chung, MD, of Yonsei Cancer Center and Yonsei University College of Medicine, discusses phase II findings from the KEYNOTE-158 study, which support the use of pembrolizumab for patients with recurrent or metastatic cervical cancer that has progressed on or after chemotherapy and whose tumors express PD-L1.

Gynecologic Cancers

Hormonal IUD May Be a Potential Nonsurgical Treatment for Early Endometrial Cancer or Precancer

An intrauterine device, or IUD, that releases the hormone levonorgestrel appears to be an effective treatment for endometrial precancer and early-stage endometrial cancer, according to new study results presented by Andreas Obermair, MD, at the Society of Gynecologic Oncology (SGO) 2021 Virtual...

gynecologic cancers

Shannon N. Westin, MD, on Treating Endometrial Cancer With Enzalutamide, Paclitaxel, and Carboplatin

Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results from the ENPAC trial, which showed the combination of enzalutamide, paclitaxel, and carboplatin yielded promising clinical outcomes in chemotherapy-naive advanced or recurrent endometrioid cancer (ID # 10244).

Gynecologic Cancers

Maintenance Olaparib Yields Strong and Sustained Benefit in Ovarian Cancer

In the 5-year follow-up of the pivotal SOLO-1 trial in women with advanced ovarian cancer and a BRCA1/2 mutation, maintenance treatment with olaparib led to a doubling in progression-free survival. William H. Bradley, MD, presented these findings at the Society of Gynecologic Oncology (SGO) 2021...

gynecologic cancers

Ursula A. Matulonis, MD, on Ovarian Cancer: Niraparib as Maintenance Therapy

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses phase III results from the ENGOT-OV16/NOVA study on the long-term safety and efficacy of niraparib as maintenance therapy in patients with platinum-sensitive ovarian cancer with either a BRCA mutation or a tumor with high-grade serous histology. Women in the study have responded to their most recent chemotherapy containing a platinum agent (ID #: 11139).

Gynecologic Cancers

Benefit of Niraparib Maintenance Therapy Extends Beyond First Disease Progression in Recurrent Ovarian Cancer

The PARP (poly [ADP-ribose] polymerase) inhibitor niraparib is safe for long-term use and effective as maintenance treatment in patients with platinum-sensitive recurrent ovarian cancer, according to data presented by Ursula A. Matulonis, MD, at the Society of Gynecologic Oncology (SGO) 2021...

Gynecologic Cancers

Phase III ARIEL4 Trial Confirms Benefit of Rucaparib in BRCA-Mutated Relapsed Ovarian Cancer

In patients with BRCA-mutated, advanced, relapsed ovarian cancer, treatment with the PARP (poly [ADP-ribose] polymerase) inhibitor rucaparib led to a significant improvement in progression-free survival compared with standard-of-care chemotherapy. These results from the international phase III...

Gynecologic Cancers

Frailty May Impact Surgical Outcomes in Patients With Ovarian Cancer

Frailty may be a better predictor of poor surgical outcomes in patients with ovarian cancer than age, according to two studies reported at the Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer. Researchers found that frail patients are less likely to undergo...

gynecologic cancers

Morcos N. Nakhla, MS, on Surgical Outcomes for Frail Patients With Ovarian Cancer

Morcos N. Nakhla, MS, a second-year student at the David Geffen School of Medicine at UCLA, discusses data showing that a higher surgical volume is associated with better outcomes for frail patients undergoing surgery for ovarian cancer. Over the 12-year study period, mortality decreased for all women with ovarian cancer, despite a concurrent increase in frail patients (ID #10209).

gynecologic cancers
covid-19

Brian M. Slomovitz, MD, on the Impact of COVID-19 on Gynecologic Cancer Research

Brian M. Slomovitz, MD, of Florida International University, describes how emphasizing diversity and shifting away from clinical trials at universities helped The GOG Foundation, Inc., increase patient accrual by 50% in 2020 (ID # 10215).

gynecologic cancers
global cancer care

Edward L. Trimble, MD, MPH, on Cervical Cancer: A Global WHO Initiative

Edward L. Trimble, MD, MPH, of the National Cancer Institute, discusses the World Health Organization’s global strategy to speed the elimination of cervical cancer through vaccination, screening, treatment, and training for multidisciplinary teams in gynecologic oncology care. This marks the first time that 194 countries have committed to such an effort (ID # 10203).

gynecologic cancers
genomics/genetics

William H. Bradley, MD, on Ovarian Cancer: 5-Year Follow-up on Maintenance Olaparib

William H. Bradley, MD, of the Medical College of Wisconsin, discusses results from the SOLO-1 trial on maintenance olaparib after first-line platinum-based chemotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Almost half of the patients treated with olaparib in the study were disease-free at 5 years, vs 20% of those treated with placebo (ID# 10224).

Gynecologic Cancers
COVID-19
Immunotherapy

Recent Chemotherapy or Immunotherapy for Gynecologic Cancer Does Not Raise Risk of Death Due to COVID-19

Although some studies show that patients with cancer have a greater risk of health complications from COVID-19, a new study has found that recent chemotherapy or immunotherapy for gynecologic cancer does not raise the risk of hospitalization or death due to COVID-19. The study results were...

Gynecologic Cancers
Genomics/Genetics

PARP Inhibition Shows Efficacy in Ovarian Cancer Regardless of Number of Prior Lines of Chemotherapy, BRCA Mutation Status

Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, according to data presented from the phase II LIGHT study by Karen A. Cadoo, MD, at the Society of...

Gynecologic Cancers
Issues in Oncology

Survey Reveals Workplace Bullying, Gender Discrimination, and Microaggressions Not Uncommon for Women Gynecologic Oncologists

In a survey of 250 female gynecologic oncologists, more than half reported experiencing instances of bullying, gender discrimination, or microaggressions. They also reported that having a female department chair provided no buffer against these forms of gender harassment or discrimination in the...

Gynecologic Cancers
Immunotherapy

Pembrolizumab/Lenvatinib May Improve Survival in Advanced Endometrial Cancer

In the first report from the pivotal phase III KEYNOTE-775/Study 309 trial, the combination of lenvatinib and pembrolizumab significantly improved multiple outcomes compared to standard single-agent chemotherapy in patients with advanced, metastatic, or recurrent endometrial cancer that had...

gynecologic cancers

Rebecca S. Kristeleit, MD, PhD, on Relapsed Ovarian Cancer: Rucaparib vs Chemotherapy

Rebecca S. Kristeleit, MD, PhD, of the University College London and UCL Cancer Institute, discusses efficacy and safety results from the phase III ARIEL4 study, which showed that rucaparib improved progression-free survival vs standard-of-care chemotherapy in patients with BRCA-mutated, platinum-resistant, or platinum-sensitive relapsed ovarian cancer (ID #10191).

gynecologic cancers
immunotherapy

Vicky Makker, MD, on Endometrial Cancer: Lenvatinib Plus Pembrolizumab

Vicky Makker, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III findings showing that lenvatinib plus pembrolizumab may improve overall and progression-free survival, as well as overall response rate, compared with treatment of physician’s choice for advanced endometrial cancer. These results were achieved regardless of mismatch repair status following platinum-based chemotherapy (ID #10191).

Issues in Oncology
Gynecologic Cancers
Cost of Care

Is HPV Vaccination for Adults Aged 26 and Older Cost-Effective?

Vaccinating adults aged 26 and older against the human papillomavirus (HPV) may not be cost-effective, according to a new study published by Kim et al in PLOS Medicine. “Our study found that the added health benefit of increasing the vaccination age limit beyond 26 years is minimal, and that the...

Gynecologic Cancers

Secondary Cytoreduction Plus Chemotherapy vs Chemotherapy Alone in Relapsed Platinum-Sensitive Epithelial Ovarian Cancer

In a Chinese phase III trial (SOC-1) reported in The Lancet Oncology, Shi et al found that secondary cytoreduction followed by chemotherapy significantly prolonged progression-free survival vs chemotherapy alone in patients with platinum-sensitive relapsed epithelial ovarian cancer. No significant...

Gynecologic Cancers
Head and Neck Cancer
Thyroid Cancer
Hematologic Malignancies

FDA Pipeline: Designations in Ovarian, Head/Neck, and Thyroid Cancers

Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a novel immunotherapy for the treatment of ovarian cancer as well as Breakthrough Therapy designation to treatments for HRAS-mutant head and neck squamous cell carcinoma and previously treated thyroid cancer....

Gynecologic Cancers

Recent Study Examines Potential New Therapies, Assessment of Biomarkers in Endometrial Cancer

In a new study published by Merritt et al in Cancer Epidemiology, Biomarkers & Prevention, researchers demonstrated that sex hormones and insulin growth factors may be associated with recurrence risk in patients with endometrial cancer. The findings suggest endocrine-targeted therapies and an...

Gynecologic Cancers
Immunotherapy

Bevacizumab Beyond Disease Progression Plus Carboplatin-Based Doublet in Platinum-Sensitive Ovarian Cancer

In the phase III MITO16b/MANGO–OV2/ENGOT–ov17 trial, investigators found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer...

Breast Cancer
Gynecologic Cancers
Genomics/Genetics

Trends in Germline Genetic Testing in Women Diagnosed With Breast or Ovarian Cancer

In a study of germline genetic testing in women diagnosed with breast or ovarian cancer reported in the Journal of Clinical Oncology, Allison W. Kurian, MD, MSc, and colleagues found that undertesting persists in patients with ovarian cancer, and that most pathogenic variants are found in 20 breast ...

Issues in Oncology
COVID-19
Breast Cancer
Lung Cancer
Gynecologic Cancers
Global Cancer Care

Impact of COVID-19 on Cancer Care Has Been ‘Profound,’ According to WHO

More than a year since the new coronavirus crisis began, its impact on cancer care has been stark, with “50% of governments (having) cancer services partially or completely disrupted because of the pandemic,” said André Ilbawi, MD, of the World Health Organization’s (WHO) Department of...

Gynecologic Cancers

Addition of Wee1 Inhibitor Adavosertib to Gemcitabine in Platinum-Resistant/Refractory Recurrent Ovarian Cancer

In a phase II trial reported in The Lancet, Lheureux et al found that the addition of the oral Wee1 inhibitor adavosertib to gemcitabine significantly improved progression-free survival in patients with platinum-resistant/refractory recurrent ovarian cancer. As related by the investigators, the...

Breast Cancer
Gynecologic Cancers
Colorectal Cancer

Rates of Eligible People Missing Timely Cancer Screenings: A Canadian Analysis

New research published by Abdel-Rahman in JNCCN—Journal of the National Comprehensive Cancer Network found more than one-third of eligible people miss timely screening tests for colorectal cancer, and at least one-quarter appear to miss timely screening tests for breast and cervical cancers....

Issues in Oncology
Lung Cancer
Gynecologic Cancers

Record Drop in Cancer Mortality for Second Straight Year Due to Improved Lung Cancer Treatment Reported in ‘Cancer Statistics, 2021’

Overall cancer death rates in the United States dropped continuously from 1991 through 2018, for a total decrease of 31%, including a 2.4% decline from 2017 to 2018. These findings were reported in the American Cancer Society’s “Cancer Statistics, 2021” article, published by Rebecca L. Siegel, MPH, ...

Lung Cancer
Gynecologic Cancers
Issues in Oncology

Transmission of Maternal Cancer in Two Infants From Mothers With Cervical Cancer During Delivery

In a brief report published in The New England Journal of Medicine, Arakawa et al described the identification of lung cancer in two children that likely resulted from transmission of maternal cervical cancer tumor cells during vaginal delivery. As noted by the investigators, the transmission of...

Gynecologic Cancers

Outcomes After Neoadjuvant Carboplatin/Paclitaxel in Women With Ovarian Cancer and Planned Delayed Surgery: ICON8 Analysis

In a post hoc analysis from the ICON8 trial reported in The Lancet Oncology, Morgan et al found evidence indicating that the evaluation of response to platinum-based neoadjuvant therapy in women with ovarian carcinoma using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, should...

Gynecologic Cancers
Global Cancer Care

Global Burden of Cervical Cancer and Association With HIV

A research team has quantified the effects of infection with the human immunodeficiency virus (HIV) on the development of cervical cancer. Their results show that the risk of developing cervical cancer is six times higher in women who are infected with HIV, and that women who live in Southern and...

Gynecologic Cancers
Breast Cancer

Study Clarifies Time-Dependent Effects of Oral Contraceptives on Risk of Ovarian, Endometrial, and Breast Cancers

A comprehensive study involving more than 250,000 women showed that oral contraceptive use may be protective against the development of ovarian and endometrial cancers, but the effect on lifetime risk of breast cancer is more limited. The protective effect on ovarian and endometrial cancers was...

Gynecologic Cancers

Neoadjuvant Chemotherapy and Overall Survival in Metastatic Endometrial Cancer

In a National Cancer Database analysis reported in JAMA Network Open, Tobias et al found that receipt of neoadjuvant chemotherapy was associated with improved short-term but not long-term survival vs primary debulking surgery in patients with metastatic endometrial cancer. As stated by the...

Gynecologic Cancers
Immunotherapy

Gemogenovatucel-T Maintenance in Stage III/IV Ovarian Cancer

In the phase IIb VITAL trial reported in The Lancet Oncology, Rocconi et al found that front-line maintenance with the autologous tumor cell vaccine gemogenovatucel-T did not improve recurrence-free survival vs placebo in patients with stage III/IV ovarian cancer in clinical complete response after ...

Gynecologic Cancers

Study Shows Sentinel Lymph Node Biopsy to Be 'Viable Option' for Surgical Staging of Endometrial Cancer

Sentinel lymph node biopsy “had similar diagnostic accuracy and prognostic ability as lymphadenectomy in patients with high-grade endometrial cancer at greatest risk for nodal metastases,” according to the SENTOR trial, a prospective cohort study of 156 patients with clinical stage I disease. Using ...

Gynecologic Cancers
Immunotherapy

Pembrolizumab in Combination With a Therapeutic DNA Vaccine for HPV-Positive Advanced Cervical Cancer

As reported in The Lancet Oncology by Youn et al, interim results of a Korean phase II trial indicated activity with the combination of pembrolizumab plus the therapeutic DNA vaccine GX-188E in patients with human papillomavirus (HPV)-16– or HPV-18–positive advanced cervical cancer. GX-188E...

Gynecologic Cancers
Immunotherapy

Subgroup Analysis of Japanese Patients With Ovarian Cancer Treated With Maintenance Olaparib/Bevacizumab

Findings from a subgroup analysis of the phase III PAOLA-1/ENGOT-ov25 study presented by Fujiwara et al at the ESMO Asia Virtual Congress 2020 showed that the addition of olaparib to bevacizumab maintenance following standard platinum-based therapy plus bevacizumab provided a progression-free...

Breast Cancer
Gynecologic Cancers
Genomics/Genetics

Trends in Positive BRCA Test Results Among Women Aged 65 and Older in the United States

In a study reported in JAMA Network Open, Guo et al found that the proportion of positive BRCA genetic test results markedly declined between 2008 and 2018 among women aged ≥ 65 years in the United States, with the trend likely reflecting what the investigators call a loosening of testing criteria...

Gynecologic Cancers

Image-Guided IMRT Reduces GI Toxicity Without Compromising Pelvic Recurrence in Intermediate- to High-Risk Cervical Cancer

Post-hysterectomy image-guided intensity-modulated radiation therapy (IMRT) was superior to three-dimensional conformal radiation therapy (3D-CRT) in reducing the side effects of pelvic radiation while achieving similar tumor control in women with high-risk cervical cancer, according to the final...

Gynecologic Cancers
Immunotherapy

Pembrolizumab Plus Bevacizumab and Oral Metronomic Cyclophosphamide for Recurrent Ovarian Cancer

In a single-institution phase II trial reported in JAMA Oncology, Zsiros et al found that the combination of pembrolizumab with bevacizumab and oral metronomic cyclophosphamide produced objective response in approximately half of women with recurrent ovarian cancer taking part in the study....

Breast Cancer
Gynecologic Cancers
Genomics/Genetics

Screening Younger Women for Variants Linked to Breast and Ovarian Cancers May Be Cost-Effective

Population-wide screening for genetic variants linked to hereditary breast and ovarian cancers may be cost-effective in women between the ages of 20 and 35, according to a study published by Guzauskas et al in JAMA Network Open. However, screening for older women was not cost-effective, the...

Gynecologic Cancers

Sentinel Lymph Node Biopsy vs Lymphadenectomy for Staging of Intermediate- and High-Grade Endometrial Cancers

In a Canadian prospective cohort study (SENTOR) reported in JAMA Surgery, Cusimano et al found that sentinel lymph node biopsy showed “acceptable diagnostic accuracy” compared with lymphadenectomy in detecting nodal metastatic disease in patients with intermediate- and high-grade endometrial...

Breast Cancer
Lung Cancer
Gynecologic Cancers

FDA Approves Companion Diagnostic for Three Targeted Therapies for Advanced Ovarian, Breast, and Non–Small Cell Lung Cancers

On October 27, 2020, the U.S. Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx test for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies. The new indications are for alpelisib...

Gynecologic Cancers

Expert Point of View: Andreas du Bois, MD, PhD

The invited discussant of the phase III INOVATYON trial was Andreas du Bois, MD, PhD, Chairman of the Department of Gynecology and Gynecologic Oncology at Kliniken Essen Mitte, Germany, and Chairman of the AGO Study Group. As Dr. du Bois explained, the study “dealt with an old question: Does...

Gynecologic Cancers

INOVATYON: Platinum-Based Regimens Remain Standard of Care in Recurrent Platinum-Sensitive Ovarian Cancer

Yet another blow has been dealt for the alkylating agent trabectedin in advanced ovarian cancer. The international phase III INOVATYON study found no improvement in overall or progression-free survival for trabectedin plus pegylated liposomal doxorubicin (PEG-LD) vs carboplatin/PEG-LD in patients...

Gynecologic Cancers
Immunotherapy

Expert Point of View: Ana Oaknin, MD, PhD

The innovaTV 204 trial’s invited discussant, Ana Oaknin, MD, PhD, Head of the Gynecologic Cancer Program at Vall d’Hebron Institute of Oncology in Barcelona, was encouraged by the study’s findings. “Of note, the response rate was 24%, the time to response was short, and the median duration of...

Advertisement

Advertisement

Advertisement